Navigation Links
First Breast Cancer Patient Receives Treatment in National Electronic Brachytherapy Registry Launched by Three Physician Societies
Date:6/24/2008

Multi-Disciplinary Oversight Panel Includes American Brachytherapy Society, American Society of Breast Surgeons and American College of Radiation

Oncology

SUNNYVALE, Calif., June 24 /PRNewswire/ -- Xoft, Inc. today announced the launch and of the EXIBT Study (Electronic Xoft Intersociety Brachytherapy Trial), a national Electronic Brachytherapy patient registry under oversight from three national physician societies, the American Brachytherapy Society (ABS), the American Society of Breast Surgeons (ASBrS), and the American College of Radiation Oncology (ACRO). The first patient was successfully enrolled and treated in the registry by Drs. Peter Beitsch of the Dallas Breast Center and Timothy Nichols of the Northpoint Cancer Center in Dallas, Texas.

With an enrollment goal of 400 patients, the objective of the multi-center study is to assess the long-term safety and efficacy of the Xoft Axxent(R) Electronic Brachytherapy System for the treatment of early stage breast cancer patients. The primary endpoint is the measurement and quantification of skin and subcutaneous toxicities through five year follow-up. An important additional primary endpoint includes a quality of life questionnaire based on patient experience with this new form of radiation therapy. Secondary endpoints assess local-regional breast failure and patient survival through five years as well as device performance.

"From earlier diagnosis to decreased morbidities and treatment times and ultimately, improved survival, we have made great strides in treating women with breast cancer. For many women, post lumpectomy radiation therapy can now be completed in one week with brachytherapy compared to the 6-7 weeks required for external beam therapy," said Peter Beitsch, MD, co-Principal Investigator of EXIBT and the surgeon for the first patient on the registry. Dr. Beitsch is director of the Dallas Breast Center and a Board Member of the American S
'/>"/>

SOURCE Xoft, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... JACKSONVILLE, Fla. , Aug. 28, 2015  With ... reaching deadlier heights, Jacksonville ... Philip Hemphill is helping to explain why ... Fentanyl is approximately 40 to 50 times more potent ... by recreational users as heroin, the risk of death ...
(Date:8/28/2015)... , Aug. 28, 2015  CytomX Therapeutics, Inc., a ... cancer, today announced the filing of a registration statement ... Commission (SEC) relating to a proposed initial public offering ... be offered and the price range for the offering ... its common stock under the symbol "CTMX" on the ...
(Date:8/28/2015)... 28, 2015 Research ... addition of the "Investigation Report on China,s ... Originally discovered by Welfide (Mitsubishi Tanabe ... Ltd) as an inflammatory drug, pranoprofen was later ... Ltd under the trade name of pranopulin for ...
Breaking Medicine Technology:Lakeview Health's Dr. Philip Hemphill Explains Why Heroin Addicts Are Now Dying of Fentanyl Overdoses 2CytomX Files Registration Statement for Proposed Initial Public Offering 2Investigation Report on China's Pranoprofen Market, 2010-2019 2
... Calif., Feb. 28, 2011 Varian Medical Systems, Inc. (NYSE: ... into a new agreement with Bank of America N.A. to ... share repurchase program.   Under the accelerated repurchase ... N.A. and receive approximately 3.5 million shares, or 85% of ...
... 2011 S*BIO Pte Ltd today announced that its ... (PK/PD) properties leading to significant anti-tumor efficacy in rapamycin-sensitive ... in vitro data on SB2343 were presented ... on Targeting PI3K/mTOR Signaling in Cancer held in San ...
Cached Medicine Technology:Varian Medical Systems Announces New $280 Million Accelerated Stock Repurchase 2Varian Medical Systems Announces New $280 Million Accelerated Stock Repurchase 3S*BIO's Novel Dual mTOR/PI3 Kinase Inhibitor SB2343 Demonstrates Excellent PK/PD Properties Leading to Significant Anti-Tumor Efficacy in Xenograft Models 2S*BIO's Novel Dual mTOR/PI3 Kinase Inhibitor SB2343 Demonstrates Excellent PK/PD Properties Leading to Significant Anti-Tumor Efficacy in Xenograft Models 3
(Date:8/29/2015)... ... August 29, 2015 , ... ... localized area with stretching, soft tissue manipulation. Platelet rich plasma injections also have ... through research to improve treatment outcomes. This localized treatment seems to address ...
(Date:8/28/2015)... Madre, CA (PRWEB) , ... August 28, 2015 ... ... solutions to wound center management, Decatur County Memorial Hospital recently transitioned management companies ... model of Wound Center Management for their outpatient wound center. , Transitioning ...
(Date:8/28/2015)... CA (PRWEB) , ... August 28, 2015 , ... An ... journey that local pizza maker Paul LaRocco has gone through to open a pizzeria ... approval and permitting process tends to take several months, but the current process, having ...
(Date:8/28/2015)... ... ... As reported by Medical Daily on August 22 , Cellfina, a non-invasive ... two years, the longest of any cellulite reduction system currently on the market. ... solution for their cellulite, according to Dr. Robert Weiss, director of the premier MD ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... 20 grams of high grade protein with zero fat, carbs, sugar, gluten, lactose ... been named a finalist for the 2015 SupplySide CPG Editor’s Choice Awards. , ...
Breaking Medicine News(10 mins):Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3
... SALT LAKE CITY, April 17 Dynatronics,Corporation (Nasdaq: ... two new,products: the DynaPro Spinal Health System for ... oscillation therapy unit., "The new DynaPro Spinal ... benefits of decompression with light therapy,core-stabilization exercises and ...
... Blue Shield of,Minnesota (Blue Cross) today released its financial ... of 0.3 percent ($25.1 million) on,full-year revenues of $8.4 ... offset $104 million in operating losses. Blue,Cross remains financially ... claims and operating expenses., More than 90 cents ...
... Heavy drinkers and heavy,smokers develop Alzheimer,s disease years ... or smoke heavily, according to research that,will be ... Anniversary,Annual Meeting in Chicago, April 12-19, 2008., ... if we can,reduce or eliminate heavy smoking and ...
... Susser, MD, DrPH, Anna Cheskis Gelman and Murray Charles ... at the Mailman School of Public Health and professor ... the 2008 Distinguished Investigator Award from NARSAD, the world,s ... Dr. Susser was selected for a study on famine ...
... The National,Association of Specialty Health Organizations (NASHO) ... Award. The recipient of the award,will be ... programs and practices., (Logo: http://www.newscom.com/cgi-bin/prnh/20070227/CLTU004LOGO ... the specialty health industry, we felt it ...
... April 17 Seven children,from across the United ... nerve rerouting surgery for patients,with spina bifida. The ... Royal Oak, Mich., The children previously required ... or endured significant incontinence. But as a result ...
Cached Medicine News:Health News:Dynatronics Introduces New DynaPro Spinal Health System and X5 'Turbo' 2Health News:Blue Cross and Blue Shield of Minnesota Releases 2007 Financial Results 2Health News:Alzheimer's Starts Earlier for Heavy Drinkers, Smokers 2Health News:Ezra Susser, MD, DrPH, receives Distinguished Investigator Award from NARSAD 2Health News:The National Association of Specialty Health Organizations to Recognize Excellence in Technology Education With Industry Award 2Health News:Beaumont Sees Results in Nation's 1st Urinary Nerve Rewiring Surgeries for Spina Bifida Patients 2Health News:Beaumont Sees Results in Nation's 1st Urinary Nerve Rewiring Surgeries for Spina Bifida Patients 3
... x 7.5 x 80 mm. Storz ... line designed by Harvey A. Lincoff, ... closed cell sponge which is non-toxic ... rounded edges to minimize scleral intrusion. ...
... 7.5 x 80 mm. Storz offers ... designed by Harvey A. Lincoff, M.D. ... cell sponge which is non-toxic and ... edges to minimize scleral intrusion. These ...
Thin silicone pad implant. Indications: For closing scleral ruptures. Overall length: 7.8 mm....
... Size: 5.0 x 2.5 x 80 mm. Half ... by Harvey A. Lincoff, M.D. has been modified ... design. The material is a closed cell sponge ... with rounded edges to minimize scleral intrusion. These ...
Medicine Products: